An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers
Latest Information Update: 14 Feb 2025
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Mirvetuximab soravtansine (Primary) ; SL 172154 (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Shattuck Labs
Most Recent Events
- 11 Feb 2025 Status changed from active, no longer recruiting to completed.
- 03 Oct 2024 Planned End Date changed from 1 Apr 2025 to 1 Nov 2024.
- 03 Oct 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Nov 2024.